Replies to post #28 on Syndax Pharmaceuticals Inc (SNDX)

[tika1]

After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.